NEPHROS, INC. Accretion Expense
NEPHROS, INC. (NEPH) reported Accretion Expense of $14.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-03.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AccretionExpense · last filed 2022-03-03
- NEPHROS, INC. accretion expense for fiscal 2020 was $14.00K, a 27350.98% increase from fiscal 2019.
- NEPHROS, INC. accretion expense for fiscal 2019 was $51.00.
| Period end | Accretion Expense 12 month |
|---|---|
| 2020-12-31 | $14.00K 10-K · filed 2022-03-03 |
| 2019-12-31 | $51.00 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sensus Healthcare, Inc. (SRTS) | United States | $0.048B | -3.24 |
| SANUWAVE Health, Inc. (SNWV) | United States | $0.041B | 5.47 |
| Spectral AI, Inc. (MDAI) | United States | $0.052B | |
| Xtant Medical Holdings, Inc. (XTNT) | United States | $0.053B | |
| TELA Bio, Inc. (TELA) | United States | $0.057B | -0.82 |
| InspireMD, Inc. (NSPR) | $0.033B | ||
| PAVmed Inc. (PAVM) | United States | $0.031B | -3.00 |
| Glucotrack, Inc. (GCTK) | United States | $0.027B | |
| ACCURAY INC (ARAY) | United States | $0.027B | -0.63 |
| DarioHealth Corp. (DRIO) | $0.066B | -1.39 |